MCC-22-GU-80: Phase II Study of Pembrolizumab in Combination with Radiation with or without Olaparib in Localized High-risk Prostate Cancer

Grants and Contracts Details

StatusActive
Effective start/end date10/12/22 → 9/18/25

Funding

  • Merck Sharp & Dohme Corporation: $250,000.00